EPS Revisions Trigger Double-Digit Gains: ACHV Leads 26.0% Surge
Five stocks detected by our EPS revision screener posted double-digit gains: ACHV surged 26.0%, KURA +24.2%, ARGX +21.3%, REED +20.6%, and SLS +17.7%. Each was flagged after a significant upward EPS estimate revision, with earnings or trial data reinforcing the move.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| ACHV | Healthcare | 2026-08-11 | N/A | +26.0% |
| KURA | Healthcare | 2026-08-13 | N/A | +24.2% |
| ARGX | Healthcare | 2026-08-14 | N/A | +21.3% |
| REED | Consumer Defensive | 2026-08-13 | +12.5pp | +20.6% |
| SLS | Healthcare | 2026-08-12 | +11.9pp | +17.7% |
Why did ACHV stock jump in August 2026?
ACHV jumped 26.0% (from $6.77 to $8.53) after the screener flagged its EPS growth estimate at 31.2% on August 11.
The gain followed Q2 results that revealed a $354 million private placement and a strengthened leadership team, clearing a path to the anticipated FDA approval in H1 2027. The stock moved on financing and execution de-risking, not just the estimate bump.
ACHV EPS revision history → · Screener snapshot from 2026-08-11 →
FAQ: ACHV
Why did ACHV stock jump in August 2026?
ACHV jumped 26.0% after an EPS revision detection on August 11, supported by Q2 results and a $354 million private placement for FDA approval readiness.
Is ACHV a buy after the rally?
The rally reflects strong financing and regulatory progress, but the stock's next catalyst is the FDA approval decision expected in H1 2027.
What is ACHV's EPS growth estimate?
ACHV's current EPS growth estimate for next year is 31.2%, which triggered the screener's detection on August 11.
Why did KURA stock jump in August 2026?
KURA jumped 24.2% (from $10.09 to $12.53) after analysts revised its next-year EPS growth estimate to 25.6% on August 13.
The Q2 earnings beat, which saw a $0.77 loss per share versus the $0.89 estimate, and the 57% sequential revenue jump in KOMZIFTI reinforced the revision. Commercial traction and positive frontline AML data supported the move.
KURA EPS revision history → · Screener snapshot from 2026-08-13 →
FAQ: KURA
Why did KURA stock jump?
KURA rose 24.2% after an EPS revision was detected on August 13, following a Q2 loss that beat expectations and strong KOMZIFTI sales growth.
Is KURA a buy after the rally?
Given the EPS estimate revision to 25.6% growth and commercial momentum, the stock is attractive, but monitor trials and competition.
What caused KURA's surge?
The surge was driven by an EPS revision detection on August 13 and Q2 results that beat expectations, with KOMZIFTI revenue up 57% sequentially.
Why did ARGX stock jump in August 2026?
ARGX jumped 21.3% (from $851.29 to $1032.86) after its EPS growth estimate was revised to 31.6% on August 14.
The move accelerated on August 17 when the Phase 3 ALKIVIA trial of efgartigimod met its primary endpoint in autoimmune myositis. The positive data expanded the company's commercial opportunity beyond existing indications, validating the higher EPS outlook.
ARGX EPS revision history → · Screener snapshot from 2026-08-14 →
FAQ: ARGX
Why did ARGX stock jump?
ARGX rose 21.3% after an EPS revision to 31.6% growth on August 14, with the rally boosted by positive Phase 3 data in autoimmune myositis.
What caused ARGX's surge?
The surge was fueled by the EPS revision detection and the ALKIVIA trial success that showed clinically meaningful benefit in myositis.
What is ARGX's EPS growth estimate?
ARGX's next-year EPS growth estimate is 31.6%, which triggered the screener's detection on August 14.
Why did REED stock jump in August 2026?
REED jumped 20.6% (from $0.92 to $1.11) after its EPS growth estimate was revised upward from 54.5% to 66.9% on August 13.
The revision followed Q2 earnings that showed gross margin expansion to 24% from 8% and a 29% reduction in net loss, despite weaker revenue. Investors focused on improving profitability and cost controls, not the top-line miss.
REED EPS revision history → · Screener snapshot from 2026-08-13 →
FAQ: REED
Why did REED stock jump?
REED jumped 20.6% after an EPS revision from 54.5% to 66.9% growth, supported by strong gross margin improvement to 24% and lower operating losses.
Is REED a buy after the rally?
The EPS revision and margin improvement signal a turnaround, but the stock remains speculative given the revenue decline.
What caused REED's surge?
The surge was driven by an upward EPS estimate revision and Q2 results showing gross margin tripling, despite sales falling 21%.
Why did SLS stock jump in August 2026?
SLS jumped 17.7% (from $11.77 to $13.85) after its EPS growth estimate was revised from 40.5% to 52.4% on August 12.
The revision coincided with an analyst price target hike to $35 from $25, citing SLS009's lead in the CDK9 race with Phase 2 data expected in Q4. Positive trial momentum and the narrower quarterly loss supported the gain.
SLS EPS revision history → · Screener snapshot from 2026-08-12 →
FAQ: SLS
Why did SLS stock jump?
SLS rose 17.7% after an EPS revision to 52.4% growth, with an analyst's 200% upside call reinforcing the price move.
What is SLS's EPS growth estimate?
SLS's next-year EPS growth estimate is 52.4%, up from 40.5%, reflecting improved operating outlook.
What caused SLS's surge?
The surge was driven by the EPS revision detection and a price target hike following positive SLS009 trial positioning, with data due in Q4.
Today's top performers confirm that EPS estimate revisions remain a reliable early indicator of strong price follow-through, particularly in biotech and turnaround stories. Investors are rewarding clear catalysts such as trial data, financing, and margin improvements that back the revised estimates.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →